Illumina, Inc. (NASDAQ:ILMN) – Equities researchers at First Analysis issued their Q1 2020 EPS estimates for Illumina in a research note issued on Thursday, January 30th. First Analysis analyst T. Marshbanks anticipates that the life sciences company will earn $1.23 per share for the quarter. First Analysis also issued estimates for Illumina’s Q2 2020 earnings at $1.62 EPS, Q4 2020 earnings at $2.15 EPS and FY2020 earnings at $6.90 EPS.
A number of other equities analysts have also recently weighed in on ILMN. Piper Jaffray Companies dropped their price target on Illumina from $348.00 to $341.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. Guggenheim initiated coverage on Illumina in a research note on Friday, October 25th. They issued a “buy” rating and a $350.00 price target on the stock. BidaskClub lowered Illumina from a “strong-buy” rating to a “buy” rating in a research report on Friday. Zacks Investment Research lowered Illumina from a “hold” rating to a “sell” rating and set a $341.00 price objective for the company. in a research report on Monday, January 20th. Finally, ValuEngine lowered Illumina from a “buy” rating to a “hold” rating in a research report on Friday, December 20th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and twelve have issued a buy rating to the company. Illumina currently has an average rating of “Buy” and a consensus target price of $335.13.
Shares of ILMN opened at $290.07 on Monday. The business’s 50-day moving average price is $325.45 and its 200 day moving average price is $306.19. The stock has a market capitalization of $42.64 billion, a P/E ratio of 42.97, a P/E/G ratio of 2.16 and a beta of 1.05. Illumina has a 1-year low of $263.30 and a 1-year high of $380.76. The company has a current ratio of 6.82, a quick ratio of 6.15 and a debt-to-equity ratio of 0.41.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Wednesday, January 29th. The life sciences company reported $1.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.58 by $0.12. The firm had revenue of $953.00 million for the quarter, compared to analysts’ expectations of $950.16 million. Illumina had a return on equity of 22.78% and a net margin of 28.27%. Illumina’s revenue was up 9.9% on a year-over-year basis. During the same quarter last year, the business posted $1.32 EPS.
In other Illumina news, SVP Phillip G. Febbo sold 155 shares of the firm’s stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $300.00, for a total transaction of $46,500.00. Following the completion of the sale, the senior vice president now directly owns 1,506 shares in the company, valued at approximately $451,800. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Oene Mark Van sold 625 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $330.99, for a total value of $206,868.75. Following the sale, the senior vice president now owns 11,578 shares of the company’s stock, valued at $3,832,202.22. The disclosure for this sale can be found here. Insiders have sold a total of 3,727 shares of company stock valued at $1,204,837 over the last 90 days. Corporate insiders own 0.38% of the company’s stock.
Several institutional investors have recently made changes to their positions in ILMN. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in shares of Illumina by 64.8% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,315,437 shares of the life sciences company’s stock valued at $400,182,000 after buying an additional 517,226 shares during the last quarter. Nikko Asset Management Americas Inc. lifted its holdings in shares of Illumina by 80.9% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 753,124 shares of the life sciences company’s stock valued at $229,115,000 after buying an additional 336,821 shares during the last quarter. California Public Employees Retirement System lifted its holdings in shares of Illumina by 33.0% during the 3rd quarter. California Public Employees Retirement System now owns 324,248 shares of the life sciences company’s stock valued at $98,643,000 after buying an additional 80,523 shares during the last quarter. Voya Investment Management LLC lifted its holdings in shares of Illumina by 14.2% during the 3rd quarter. Voya Investment Management LLC now owns 464,957 shares of the life sciences company’s stock valued at $141,449,000 after buying an additional 57,798 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Illumina by 9.0% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 692,524 shares of the life sciences company’s stock valued at $210,680,000 after buying an additional 56,930 shares during the last quarter. Institutional investors and hedge funds own 91.71% of the company’s stock.
About Illumina
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Further Reading: What is a stock buyback?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
